As of close of business last night, Intra-Cellular Therapies Inc’s stock clocked out at $64.37, down -1.62% from its previous closing price of $65.43. In other words, the price has decreased by -$1.06 from its previous closing price. On the day, 539069 shares were traded.
Ratios:
To gain a deeper understanding of ITCI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.31 and its Current Ratio is at 5.41. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on January 03, 2024, initiated with a Outperform rating and assigned the stock a target price of $83.
On December 11, 2023, TD Cowen started tracking the stock assigning a Outperform rating and target price of $75.
On April 20, 2023, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $80.Morgan Stanley initiated its Overweight rating on April 20, 2023, with a $80 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 11 ’24 when Mates Sharon sold 20,565 shares for $65.21 per share. The transaction valued at 1,341,123 led to the insider holds 1,050,309 shares of the business.
Hineline Lawrence J. sold 10,121 shares of ITCI for $667,587 on Mar 11 ’24. The SVP of Finance, CFO now owns 0 shares after completing the transaction at $65.96 per share. On Mar 11 ’24, another insider, Halstead Michael, who serves as the EVP and General Counsel of the company, sold 7,345 shares for $65.97 each. As a result, the insider received 484,537 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ITCI now has a Market Capitalization of 6.23B and an Enterprise Value of 5.75B. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.42 while its Price-to-Book (P/B) ratio in mrq is 10.49. Its current Enterprise Value per Revenue stands at 12.44 whereas that against EBITDA is -36.20.
Stock Price History:
Over the past 52 weeks, ITCI has reached a high of $76.11, while it has fallen to a 52-week low of $43.18. The 50-Day Moving Average of the stock is 69.20, while the 200-Day Moving Average is calculated to be 61.32.
Shares Statistics:
It appears that ITCI traded 863.77K shares on average per day over the past three months and 644.25k shares per day over the past ten days. A total of 96.38M shares are outstanding, with a floating share count of 94.25M. Insiders hold about 2.64% of the company’s shares, while institutions hold 93.17% stake in the company. Shares short for ITCI as of Feb 29, 2024 were 3.7M with a Short Ratio of 4.28, compared to 4.07M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.82% and a Short% of Float of 4.43%.
Earnings Estimates
As of right now, 13 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.33 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.51, while EPS last year was -$0.46. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.15 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.29 and -$1 for the fiscal current year, implying an average EPS of -$0.67. EPS for the following year is $1.27, with 13 analysts recommending between $2.7 and -$0.49.
Revenue Estimates
In the current quarter, 12 analysts expect revenue to total $140.91M. It ranges from a high estimate of $148.69M to a low estimate of $134.8M. As of the current estimate, Intra-Cellular Therapies Inc’s year-ago sales were $91.98M, an estimated increase of 53.20% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $159.68M, an increase of 44.10% less than the figure of $53.20% in the same quarter last year. There is a high estimate of $165.4M for the next quarter, whereas the lowest estimate is $155.58M.
A total of 14 analysts have provided revenue estimates for ITCI’s current fiscal year. The highest revenue estimate was $671.8M, while the lowest revenue estimate was $653.2M, resulting in an average revenue estimate of $661.04M. In the same quarter a year ago, actual revenue was $464.37M, up 42.40% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $927.63M in the next fiscal year. The high estimate is $1.05B and the low estimate is $842.45M. The average revenue growth estimate for next year is up 40.30% from the average revenue estimate for this year.
